ArticleJournal of veterinary internal medicine
Clinical Value of Various Histological Factors in Cutaneous and Subcutaneous Mast Cell Tumors in 197 Dogs.
Article in Journal of veterinary internal medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Value of Various Histological Factors in Cutaneous and Subcutaneous Mast Cell Tumors in 197 Dogs.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMany histological tests have been correlated with outcome in mast cell tumors (MCTs)in dogs, but their statistical independence is uncertain.
objectiveTo investigate the clinical value of histological factors in the prognostication of dogs with MCTs. ANIMALS: One hundred and ninety-seven dogs with 199 histologically diagnosed cutaneous (n = 153) and subcutaneous (n = 43) MCTs treated surgically in primary care practice. All had a commercial prognostic panel performed (Patnaik and Kiupel grade, mitotic count, Ki67, AgNOR, KiAg, c-kit mutation in exons 8 and 11 and KIT localization).
methodsRetrospective cohort study identifying dogs from searching a commercial laboratory's records (January 2017-August 2020). Follow-up was collected from clinical records. Outcome measures included MCT specific survival (MSS) and recurrence.
resultsMultivariable Cox proportional hazard regression identified only mitotic count > 5 (HR 10.2; 95% CI 3.2-32.8; p < 0.001) predicted poorer MSS across all MCTs. In Patnaik grade I or II and Kiupel low-grade cutaneous MCTs, only c-kit mutation in exon 11 (HR 20.8; 95% CI 1.80-224.8; p = 0.015) predicted MSS. A c-kit mutation in exon 11 (HR 10.0; 95% CI 3.0-32.9; p < 0.001), age, and histological tumor free margins < 2 mm independently predicted cutaneous and subcutaneous MCT recurrence. In Patnaik grade I or II, and Kiupel low-grade cutaneous MCTs, c-kit mutation in exon 11 (HR 23.20; 95% CI 2.3-231.3; p = 0.007) and AgNOR (HR 13.73; 95% CI 1.6-115.6; p = 0.016) predicted MCT recurrence. CONCLUSION AND CLINICAL IMPORTANCE: This study suggests a comparatively greater role of c-kit mutations in exon 11 and AgNOR in the prognostication of MCTs, while Ki67 appears less important.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.